Rani Therapeutics Holdings, Inc. (RANI)

Market Cap	67.25M
Revenue (ttm)	1.03M
Net Income (ttm)	-30.02M
Shares Out	57.48M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,199
Open	1.150
Previous Close	1.150
Day's Range	1.115 - 1.160
52-Week Range	1.030 - 8.750
Beta	0.24
Analysts	Strong Buy
Price Target	11.33 (+885.22%)
Earnings Date	May 5, 2025

About RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibod...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 106
• Stock Exchange: NASDAQ
• Ticker Symbol: RANI
• Website: https://www.ranitherapeutics.com

Analyst Forecast

According to 6 analysts, the average rating for RANI stock is "Strong Buy." The 12-month stock price forecast is $11.33, which is an increase of 885.22% from the latest price.

Price Target

$11.33

(885.22% upside)

Analyst Consensus: Strong Buy